About Us – Meizon

A Journey of Innovation and Dedication

Founded in 2018, Meizon Innovation emerged from deeply personal battles with dementia and brain health challenges. This quest for breakthroughs was ignited by three pioneers, Associate Professor Wah Chin Boon, Professor Albert Frauman, and visionary CEO Liz Ferentinos, to deliver novel therapies for autism and dementia including Alzheimer’s disease and Neimann-Pick Type C disease (childhood dementia).

Core Values and Principles

Dedicated to building a robust and resilient business structure.
Board of directors and executives focused on delivering growth and value to shareholders.
An executive team proficient in strategic management and innovation.
Backed by leading scientists and advisors from around the globe.

Global health crises for Dementia and Autism

Dementia and autism are global health crises impacting millions, necessitating innovative solutions for improved outcomes.

Dementia

Affects 55 million people globally, leading to significant disability and economic costs of over US$1.3 trillion annually.

Autism Spectrum Disorder

Impacts one in every 36 children in the US as of 2020, and expected to affect one in 25 children in Australia in 2024.

Childhood Dementia

Accounts for 700,000 cases and 48,300 premature deaths worldwide each year.

Community and Social Responsibility

Extending Knowledge, Changing Lives

Our team members actively contribute to a range of scientific fields, including metabolomics, neuroscience, autoimmunity, virology, and biochemistry, helping to extend knowledge and drive innovation in the scientific community.

Breaking New Ground

Research into DL33 and M08 offers promising potential for treating brain degeneration, which would deliver personal, community and economic benefits. By enhancing brain function and cognitive performance, DL33 and M08 represent significant advancements in treatment.

Building a Bright Future

With a clear roadmap for scaling and growth, developing a solid platform for knowledge management and extensive data analysis, and a strong IP portfolio, we are proud to collaborate with sophisticated development partners and have access to commercial consulting capabilities from some of the largest consulting organisations around the globe.

Collaborating for Success

Our Leadership Team

We are proud to collaborate with sophisticated development partners and have access to commercial consulting capabilities from some of the largest consulting organisations in the world. With a highly experienced executive, commercial team, and scientific board, Meizon Innovation is perfectly aligned to collaborate with existing partnerships, entering already established customer bases and making a significant impact in the field of brain health.

For more information, partnership opportunities, or investment inquiries, we invite you to fill out our contact form. Become a part of Meizon Innovation and join us in pioneering a new era in brain health.